Jefferies raises Inovio stock price target on regulatory win
Jefferies has raised its price target on Inovio Pharmaceuticals (NASDAQ:INO) shares to $8.00 from $3.00, maintaining a Buy rating, amid the company's regulatory win with the approval of VOCERYQ. The stock has seen a significant surge of 141% over the past week, trading at $1.18. Jefferies highlighted VOCERYQ's broad adult label, no required surgery during the nine-week dosing window, and favorable tolerability as differentiators in the recurrent respiratory papillomatosis market.
The company expects at least 25,000 prevalent U.S. adult patients and plans to price the treatment at $460,000 per four-dose course.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
